We are live on
!
Find out more
Entrada Therapeutics
TRDA
TRDA
83 hedge funds and large institutions have $423M invested in Entrada Therapeutics in 2024 Q2 according to their latest regulatory filings, with 17 funds opening new positions, 42 increasing their positions, 11 reducing their positions, and 9 closing their positions.
New
Increased
Maintained
Reduced
Closed
282% more repeat investments, than reductions
Existing positions increased: 42 | Existing positions reduced: 11
89% more first-time investments, than exits
New positions opened: 17 | Existing positions closed: 9
33% more funds holding in top 10
Funds holding in top 10: 3 → 4 (+1)
15% more capital invested
Capital invested by funds: $369M → $423M (+$54M)
8% more funds holding
Funds holding: 77 → 83 (+6)
2.44% more ownership
Funds ownership: 77.46% → 79.9% (+2.4%)
Holders
83
Holders Change
+6
Holders Change %
+7.79%
% of All Funds
1.2%
Holding in Top 10
4
Holding in Top 10 Change
+1
Holding in Top 10 Change %
+33.33%
% of All Funds
0.06%
New
17
Increased
42
Reduced
11
Closed
9
Calls
$1K
Puts
–
Net Calls
+$1K
Net Calls Change
+$1K
Top Buyers
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
+$23.6M |
| 2 |
Janus Henderson Group
London,
United Kingdom
|
+$22M |
| 3 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$5.42M |
| 4 |
BlackRock
New York
|
+$2.95M |
| 5 |
Jacobs Levy Equity Management
Florham Park,
New Jersey
|
+$1.91M |
Top Sellers
| 1 |
RG
Redmile Group
San Francisco,
California
|
-$10.3M |
| 2 |
AACP
Advantage Alpha Capital Partners
San Francisco,
California
|
-$1.29M |
| 3 |
Morgan Stanley
New York
|
-$832K |
| 4 |
Citigroup
New York
|
-$721K |
| 5 |
WG
Winton Group
London,
United Kingdom
|
-$461K |
